Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Special Nutritionals

ARMS#

13044



0 - FRONT

MEDWATCH

For VOLUNTARY reporting by health professionals of adverse events and product problems FDA Use 0

FDA Use Only H Pad

Triage unit sequence # 87625

HE FOA MEDICAL PRODUCTS REPORTING PROGRAM	Page 1 Of		
A Patient information	C	Suspect medication	below if known)
Patient Identifier 2 Age at time 3. Sex 4		Name (give labeled strength & mir/let	edubolife Ind. Orst.
of event: 56	140 lbs #1	OTC Product - M.	102 0017
Date	lan d		Therapy dates (Il unknown, give duration)
of birth:	2	Dose, frequency & route used	trom/to (or best éstimato)
B. Adverse event or product problem 1 Product problem (e.g., defects/mail	functions) #1	averap TID	" approximately 7/20-78/2/
Cuteonas probuted to adverse event	#2	2	#2
(check all that apply)	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Diagnosis for use (indication)	5 Event abated after use stopped or dose reduce
death congenital anomaly required intervention to pre	event #	OTC - Markefal	ae #1 Nes no does
Infe-threatening permanunt impairment/dar	nage -	(0.1	P.II'
nospitalization – initial or prolonged other	1 1		. date (if known) #2 yes no does Apply
3 Date of 8/3 ->8/5/99 4 Date of this report 8/6/		1 Not Know #1	8 Event reappeared after
HADELL OF THE (THE AGENTAL)		12 112	#1 Dyes no Pappi
5 Describe event or problem	5~ I 	NDC # (for product problems only)	
Parient had stable made in all mas	<40m	_ =	De ☐ Span
Depression, Toy 20 dare 150 y 45 al loved	1 1	Concomitant medical products :	and therapy dates (exclude treatment of event)
Depression, Tou 20 dal 15043 Symphone 1.	it out		AUG 0 6 1999
on for 5 xeurs words of the selection of 2 weeks before the TMDTC of	20100	-	EC'D. AUG U O 17
and halfo TMUTC, or	m	H	EC 0.
Durchasel Metabolite TMUTC of or a shapping Mall- see separate enclose a shapping Mall- see separate enclosed one	oul		MEDWATCH (")
a shonoira Mall-see separate	ruxule	D. Suspect medical di	ance
a shapping Mall-see separate the for list of ingredients. Took one TIO for 2016 - Hen Hospiddize TIO for 2016 - Delegated Liver Enz	for	Brand name	
To Parks - Then Dospionie	2	Type of device MEDV	WATCH CTU
TIO for 2 wks - 7 Hen thespiral 2. The En ? Clast- Prien and elevated Liver En?	-ynd	Manufacturer name & address	4. Operator of device
Obst-Prien and elevation the de s 5607 555 B. 1: 2.5 Alk de s	250,	Ť	health profession lay user/patient
1 SLOT 533		7 4	other
Cl. A-Duein evaluation decreases	, at		
The L Evernes with Stones	2 '		> 40:21 × 8 9 904
Clest-Puen evaluation decreasing lepatre Every near were decreasing Metabolite Stopped	ا حسم	6.	5 Expiration date (moldaylyr)
alsong backet	In life	model #	(C)
- Strongly Supplemento Me		STITE OF	7 If implanted, give
6 Relevant teats/laboratory data, illuduling dates	, ,	catalog ii	
	8/5- 1	abital a	8 If explanted, give
5607 555 and/3) 225 an	_ 1	liot#	(mordayAtt)
15 and/3 : 2.5 and/s		OFF CEIVED FO	â
Bill 1.5 and/3; 2.5 and/3 Bill 1.5 and/3; 2.5 and/3 Allcalatio Dimpline 205 -7 27 EKG, (412, (gradien Entry as at	5 [1]	9 Device available leg evaluation	7 (Do not send to FDA)
Alkalahi proper e 203	, une	[AU)as 1 or [] no []	T attitued to the light and the (woldenty)
FKG, (412) (andien Entry - 2	. L.V	10. Concomitant medical product	and therapy dates (exclude treatment of event
negative.	- Slorgion		/
7 Other relevant history, including preexisting medical containers (\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
Depression 7 5475 of treatment		E. Reporter (see confi	dentiality section on back)
Genesora 1		1 Name, address & phone #	
HRT with Premain 0.63 Man-snoker at Dinler Non-Snoker at Dinler	-5-2		
HRT with lineways	σ		
I snoken al bunter o.	ļ		
Deal Functional roman	.,	2 Health professional? 3. Occ	cupation 4 Also reported to
renote Female, so alley	nes.	yes no	12.7W
Mail to: MEDWATCH or FAXO	o: FDA-0178	S Muse de NOT went your ider	ntity disclosed to distributor
5600 Flahers Lane 1-900-	FPA-0176	the manufacturer, place an "	X " in this box.

CTU^{FDA} Form 3600 (8/93)

Submission of a report does not constitute an admission that medical personnel or the product caused or contributed to the event.

Dry Nath Ind. Dist Metabolife Proprietary Blend 728m9 Guarana Concentrate (seed) (40mg naturally-occurring caffeine) Ma Huang Concentrate (acrial part) (12 mg naturally-occurring ephedrinus) Bee Pollen Crinsens (root) Ginger (100+) Lecithin Bovine Complex Daniana (leaf) Sarsaparilla (root) Golden Seal (aerial part) Nettles (leaf)

Gota Kola Caerial

Spirulina Algae

Royal Jelly

200000

Adverse Event Questionnaire

Complaint Number: <u>HFS-636 Projec</u> f # 13044 Investigator: <u>Nandy Bax76</u> KAN-DO ASSIGN. # 98-0215	en c			
Consumer Information				
Date of Report:				
□8-Other □9-Unknown				
Information on Adverse Event				
Date of Adverse Event: 8/03-05/98 Previous Adverse Effects to Product Type: Types MNo Give the site of consumption/ingestion (e.g. home, restaution): HOWE (Approx. 2 with any Metabolise)	urant,			
The following information relates to the consumers' use of the product.				
Describe the adverse event (including symptoms and the time lapse from using product to onset of symptoms): CHEST BAIN AND ELEVATED LIVEN ENTYMES following 2 weeks of falking grouducf How long did the symptoms last Give the circumstances of exposure (i.e. how much was taken, how was the product taken, how often was it taken, etc.). ONE CAPSURE/ day for 2 weeks List all Medication(s), Dietary Supplement(s), Food(s), and other product(s) used at the time of the event: Florac for Definesion / floration for the control of symptoms reoccur after reintroduction of suspected product: Dyes DNo Dunknown Did symptoms reoccur after using other products with the same ingredients: Dyes DNo Dunknown Not Applicable				
Medical Information				
Was a health care provider seen?: MYes □No Give health care provider's name, address and telephone number:				
Occupation of Health Care Provider: ⋈MD □Osteopath □Naturopath □Nurse □Pharmacist □Other (specify)				
What medical tests were performed and what were the results? DA. Comment on Medwatch form What was the medical diagnosis? * "Strongly suspect Adverse dang reaction to Metabolife What treatment(s) was given (e.g., drugs, other)? No days Were there any preexisting condition(s)/treatment(s)? florac/depression greatin/ premain/ (If YES, list them including allergies, and chronic diseases): Pyes DNo Pegadene	"* wt			

* Medications: Bremarin 0.625 mg 1.d.

Desynel 150 mg h.s.

Brozac 20 mg two tablets god. + Also taking Trazodone in

Comb. w/ Brozac for treatment

of Depression.

Desiter

Product Category
1. Adverse event attributed to: _DMedical Food (under medical supervision)
3. □Other (specify):
Information on Suspected/Alleged Product
Give the product name and manufacturer as listed on the label (including the recommended dosage/serving size, recommended duration of use, and indications for use as listed on the label):
List product ingredients (if ingredients are suspected to be present, but not verified, list as suspected): Discher here if ingredients are unknown Vife; Magnesium; Zinc; Chromium Bicolinafe Gualdua concentrate; Ginsens; Borine complex; damiana leaves; sanspanilla poof;
Nettles; goldsest; Kotukola; seinunina algae; Bee Pollen; Royal; olly
* Ma Huang Concentrate; Ginger; Lecifluin; Methocel; cRoscanne lose sodium; If a particular ingredient is suspected of contributing to the adverse event, please indicate the appropriate category below:
□Aspartame □Color Additive (please specify) □Monosodium Glutamate □Sulfite □Other_ □Unknown
Is the product label available, if yes submit a quality copy along with this questionnaire: □Yes □No □Unknown Product Sample Available: □Yes □No □Unknown
Outcome Attributed to Adverse Event: (If yes, include pertinent medical records) * Med. Nones. Affached to Summary Report - 208
Death: □Yes NO Summary Neport - 208
Life-Threatening: Mayes □No
Hospitalization: AYes □No (if YES, indicate if initial or prolonged)
Required intervention to prevent permanent impairment/damage: Yes No * stopped taking Metabolife
Did the adverse event result in a congenital anomaly: □Yes KNo

Rocal Williams

DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION KANSAS CITY DISTRICT

MEMORANDUM

November 02, 1998

To: Bridgette Wallace, CfSAN Adverse Reaction Monitoring System (ARMS) Monitor, HFS-636

From: Randy D. Baxter, CSO, Resident Post

Subject: Follow-up to HFS-636 project #13044/KAN-DO Assignment #98-0215 (Metabolife).

On 10/23/98 I obtained authorization for release of medical records from Ms. of said she had been taking Metabolife dietary supplements for two weeks prior to the onset of her illness.

Ms. initially went to 8/03/98 complaining of chest and back pain. Following an "abnormal" EKG the patient was immediately transported to via ambulance for treatment. While in the ER she was noticed to have an abnormal liver function test and was hospitalized for evaluation.

The physician's impression is as follows: "Hepatitis of unknown cause, possibly related to over-the-counter medicines with multiple herbal ingredients, including Ma Huang and guarana and several other medicines as mentioned in the History of Present Illness.", see Exhibit #2, page 4. Dr. also states "It was felt likely that she suffered liver injury from an OTC preparation that she bought two weeks prior to admission for weight loss.", see Exhibit 2, page 1.

Four pages of medical records provided by are attached as Exhibit 1. Exhibit 2 consists of 31 pages of records provided by Metabolife Distributor and was provided a leaflet regarding the product and an empty Metabolife bottle. An Adverse Event Questionnaire (IOM Ex 910-D) was completed and is also attached.

Randy Baxter, Investigator
Resident Post

attachments: